SC 13G: Oncocyte Corp

Ticker: IMDX · Form: SC 13G · Filed: Apr 22, 2024 · CIK: 1642380

Sentiment: neutral

Topics: sc-13g

AI Summary

SC 13G filing by Oncocyte Corp.

Risk Assessment

Risk Level: low

Filing Stats: 716 words · 3 min read · ~2 pages · Grade level 13.8 · Accepted 2024-04-22 13:30:07

Filing Documents

Not applicable

Item 3. Not applicable

Ownership

Item 4. Ownership (a) Amount beneficially owned 1,200,109 Common Shares (b) Percent of class 8.99 % (c) Number of shares as to which the person has (i) Sole power to vote or to direct the vote 1,200,109 Common Shares (ii) Shared power to vote or to direct the vote 0 Common Shares (iii) Sole power to dispose or to direct the disposition of 1,200,109 Common Shares (iv) Shared power to dispose or to direct the disposition of 0 Common Shares

Ownership of Five Percent or Less of a Class

Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following Page 2

Ownership of More than Five Percent on Behalf of Another Person

Item 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person Not applicable

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group Not applicable

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group Not applicable

Certifications

Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Page 3

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BIO-RAD LABORATORIES INC. Date April 22, 2024 By s Norman Schwartz Name Norman Schwartz Title President and Chief Executive Officer Page 4

View Full Filing

View this SC 13G filing on SEC EDGAR

View on Read The Filing